Aytu BioPharma Reports Q1 Fiscal 2027 Results, To Be Acquired
Aytu BioPharma reported net revenue of $14.8 million for Q1 Fiscal 2027, marking a 6.9% increase, while also agreeing to be acquired by Rosemont Pharmaceuticals for approximately $56 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed